Nasdaq:US$13.39 (+1.18) | HKEX:HK$19.90 (-0.25) | AIM:£2.09 (-0.1)
上一篇文章   |   下一篇文章
演示文稿, 科學出版物 | 2017-06-05

ASCO 2017: Fruquintinib Phase III in Metastatic Colorectal Cancer (FRESCO)

A randomized, double-blind, placebo-controlled, multi-centered phase III trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO)

Venue: American Society of Clinical Oncology Annual Meeting in Chicago, IL

Abstract #: 3508

Presenter: Dr. Jin Li, Oncologist and Director of the Tumor Department, Shanghai East Hospital, Tongji University School of Medicine

Authors: J Li, S Qin, RH Xu, J Xu, L Shen, Y Bai, Y Deng, L Yang, ZD Chen, H Zhong, H Pan, W Guo, Y Shu, Y Yuan, J Zhou

Session: Gastrointestinal (Colorectal) Cancer – Oral Abstract Session

Date & Time: Monday, June 5, 2017, 5:24 PM CDT

Location: Hall D2